Skip to main content

We are a Bio Pharma leader focused on helping to address the unmet medical needs of patients with serious diseases. In 2013, we invested $3.7 billion in the discovery and development of medicines, including key areas such as oncology, virology, immunology, cardiovascular and diabetes.

Here is a list of our company's marketed products.


TAXOLTM (paclitaxel)
SPRYCEL® (dasatinib)
IXEMPRA® (ixabepilone)
PARAPLATIN® (carboplatin)

Hepatitis B
BARACLUDE® (entecavir)

Pain Management
PERFALGANTM® (paracetamol)

Rheumatoid Arthritis
ORENCIA® (abatacept)

Disclaimer: Please consult your physician for professional medical advice and services.

© 2015 Bristol-Myers Squibb Company Legal Notice   »   Privacy Policy   »  Trademarks